Dr.GastroMayo said:

Denials are usually procedural rather than clinical, and the order that works reflects that.

Dr.GastroMayo said:

...regarding the discontinuation data for cost and coverage...

I want to reframe the discontinuation narrative. We don't say "insulin fails because blood sugar rises when you stop it." We don't say "antihypertensives fail because BP goes up without them."

Why do we apply different logic to anti-obesity medications? The answer is stigma. We still, unconsciously, believe obesity is about willpower rather than biology. The discontinuation data actually PROVES it's a chronic biological condition requiring ongoing treatment.

This reframing isn't semantic — it has implications for insurance coverage, treatment duration, and patient expectations.

Dr.GastroMayo said:

Denials are usually procedural rather than clinical, and the order that works reflects that.

This is where I part company with the consensus forming above. The affordability discussion here usually stops at individual tactics. At list price this class is out of reach for most of the people who would benefit, and no amount of appeal strategy changes that — it is a pricing problem wearing a paperwork costume.

PharmD_Rodriguez said:

The affordability discussion here usually stops at individual tactics.

My insurance denied my PA related to cost and coverage. Has anyone successfully appealed? I'm considering going compounded instead.

Dr.RenalNash said:

Dr.GastroMayo said: ...regarding the discontinuation data for cost and coverage...

Same pattern here, and in the same order. The detail I would add is minor and it is already implied above.